These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 7174153

  • 1. Effect of low estrogen combination oral contraceptive on metabolism of aspirin and phenylbutazone.
    Gupta KC, Joshi JV, Hazari K, Pohujani SM, Satoskar RS.
    Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):511-3. PubMed ID: 7174153
    [Abstract] [Full Text] [Related]

  • 2. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG, Dai Y.
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [Abstract] [Full Text] [Related]

  • 3. Plasma rifampicin levels during oral contraception.
    Gupta KC, Joshi JV, Anklesaria PS, Shah RS, Satoskar RS.
    J Assoc Physicians India; 1988 Jun; 36(6):365-6. PubMed ID: 3182712
    [Abstract] [Full Text] [Related]

  • 4. Glucose and insulin levels after six months of treatment with a triphasic oral contraceptive containing ethinyl estradiol and norethindrone.
    Spellacy WN, Ellingson AB, Tsibris JC.
    J Reprod Med; 1989 Aug; 34(8):540-2. PubMed ID: 2681750
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Sivin I, Kluft C.
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [Abstract] [Full Text] [Related]

  • 6. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [Abstract] [Full Text] [Related]

  • 7. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
    Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, Hendrix CW, Flexner C.
    Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
    [Abstract] [Full Text] [Related]

  • 8. Prospective carbohydrate metabolism studies in women using a low-estrogen oral contraceptive for one year.
    Spellacy WN, Birk SA, Buggie J, Buhi WC.
    J Reprod Med; 1981 Jun; 26(6):295-8. PubMed ID: 7019435
    [Abstract] [Full Text] [Related]

  • 9. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
    Granfors MT, Backman JT, Laitila J, Neuvonen PJ.
    Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
    [Abstract] [Full Text] [Related]

  • 10. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 11. Effect of oral contraceptives on vitamin B6 nutriture of young women.
    Vir SC, Love AH.
    Int J Vitam Nutr Res; 1980 Aug; 50(1):29-34. PubMed ID: 7390712
    [Abstract] [Full Text] [Related]

  • 12. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Stone S.
    Int J Fertil Menopausal Stud; 1993 Aug; 38 Suppl 3():117-21. PubMed ID: 8260969
    [Abstract] [Full Text] [Related]

  • 13. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM.
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [Abstract] [Full Text] [Related]

  • 14. The interaction between St John's wort and an oral contraceptive.
    Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC.
    Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A.
    Int J Fertil Menopausal Stud; 1995 Dec; 40 Suppl 2():98-104. PubMed ID: 8574257
    [Abstract] [Full Text] [Related]

  • 17. [Time course of inhibition of caffeine elimination in response to the oral depot contraceptive agent Deposiston. Hormonal contraceptives and caffeine elimination].
    Meyer FP, Canzler E, Giers H, Walther H.
    Zentralbl Gynakol; 1991 Dec; 113(6):297-302. PubMed ID: 2058339
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.